An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2018
At a glance
- Drugs [18F]-JNJ-64511070 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 28 Mar 2018 Status changed from recruiting to completed.
- 12 Jan 2018 Planned End Date changed from 29 Nov 2017 to 30 Apr 2018.
- 12 Jan 2018 Planned primary completion date changed from 29 Nov 2017 to 30 Apr 2018.